The DOI matches its Crossref record; 412 of the 412 references it cites were found in a registry or an index; none of the 354 sources its claims cite is checked for support yet.
The World Federation of Societies of Biological Psychiatry guidelines on the assessment and pharmacological treatment of compulsive sexual behaviour disorder
Open accessAbstract
OBJECTIVES: The current guidelines aim to evaluate the role of pharmacological agents in the treatment of patients with compulsive sexual behaviour disorder (CSBD). They are intended for use in clinical practice by clinicians who treat patients with CSBD. METHODS: An extensive literature search was conducted using the English-language-literature indexed on PubMed and Google Scholar without time limit, supplemented by other sources, including published reviews. RESULTS: Each treatment recommendation was evaluated with respect to the strength of evidence for its efficacy, safety, tolerability, and feasibility. Psychoeducation and psychotherapy are first-choice treatments and should always be conducted. The type of medication recommended depended mainly on the intensity of CSBD and comorbid sexual and psychiatric disorders. There are few randomised controlled trials. Although no medications carry formal indications for CSBD, selective-serotonin-reuptake-inhibitors and naltrexone currently constitute the most relevant pharmacological treatments for the treatment of CSBD. In cases of CSBD with comorbid paraphilic disorders, hormonal agents may be indicated, and one should refer to previously published guidelines on the treatment of adults with paraphilic disorders. Specific recommendations are also proposed in case of chemsex behaviour associated with CSBD. CONCLUSIONS: An algorithm is proposed with different levels of treatment for different categories of patients with CSBD.
Overview
CoChat Summary
TL;DR
The WFSBP guidelines evaluate pharmacological treatment for compulsive sexual behaviour disorder (CSBD), concluding that psychoeducation and psychotherapy are first-choice and should always be conducted. SSRIs and naltrexone are currently the most relevant off-label pharmacological treatments, with hormonal agents reserved mainly for CSBD with comorbid paraphilic disorders and specific recommendations for chemsex-associated CSBD.
Key findings
- Psychoeducation and psychotherapy are first-choice treatments and should always be conducted; there are few randomised controlled trials, and no medications carry formal indications for CSBD.
- SSRIs and naltrexone currently constitute the most relevant pharmacological treatments for CSBD, each supported by level B evidence; recommended dose ranges include naltrexone 50–200 mg/day and SSRIs at OCD-like doses (e.g., sertraline 50–200 mg/day, fluoxetine 20–80 mg/day, paroxetine 20–60 mg/day).
- In CSBD with comorbid paraphilic disorders, hormonal agents may be indicated: cyproterone acetate (level C1) and GnRH agonists (level C3) should be reserved for intense CSBD symptoms with co-occurring paraphilic disorders and at least moderate or high risk of sexual offending.
- The first placebo-controlled RCT (Lew-Starowicz et al. 2022; n = 73 heterosexual men) found self-reported CSBD severity decreased across paroxetine, naltrexone, and placebo with no between-group differences; clinical interviews found paroxetine and naltrexone more effective than placebo, and craving for sexual encounters and pornography viewing was reduced only in the paroxetine condition.
Methods
- Literature search used PubMed and Google Scholar without time limit, with keywords including hypersexual, sexual addiction, compulsive sexual behaviour, impulsive sexual behaviour, paraphilia AND medication, antiandrogens, antidepressants, SSRI, naltrexone, cyproterone acetate, medroxyprogesterone acetate, pharmacological, LHRH agonist, and GnRH agonists, supplemented by other sources including published reviews.
- Studies were included if they contained original data on treatment effectiveness of any pharmacological agent in individuals with non-paraphilic CSB; studies reporting only on patients with paraphilic CSB were excluded because they were covered in the 2020 WFSBP guidelines on paraphilic disorders, though those studies and chemsex studies were referenced.
- Each treatment recommendation was evaluated for strength of evidence for efficacy, safety, tolerability, and feasibility, and an algorithm was proposed with different treatment levels for different categories of patients with CSBD.
Limitations
- Stated: most reports on CSBD treatment are case reports or series; treatment efficacy studies have methodological biases; standardised and reliable measures of sexual behaviour are difficult; self-reports are usually used but are not reliable indices; controlled and randomised pharmacological studies are scarce and almost absent in women; comparisons between studies are difficult due to methodological differences.
- Stated: specific problems may occur when randomisation is adapted to psychological treatments, as therapists may significantly impact outcomes and controlled designs may not facilitate productive therapist–patient relationships.
- Evident: the authors describe these as “pragmatic guidelines” with less rigorous methodological standards than most WFSBP guidelines due to limited resources and randomised controlled studies, and many recommendations are off-label or based on low-level evidence such as case reports, small samples, and lack of controlled studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 8 Not valid · 279 Not checked · 92 Own results and interpretations
In the paper
“Bőthe and colleagues found a small but significant association between compulsivity and CSB in a sample of 13,778 men and women from the general population (Bőthe, Koós, et al. 2019).”
§ The World Federation of Societies of Biological Psychiatry guidelines on the assessment and pharmacological treatment of compulsive sexual behaviour disorder > Co-occurring conditions > Co-occurring psychiatric disorders
What the sources say
- Not checked yetcites Bőthe, Koós, et al. 2019
plainstates an associationn = 13,778- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Despite these high co-occurence rates, CSB was not found significantly more often than in adults without ADHD in that study (Gregorio Hertz, Turner, et al. 2022).”
§ The World Federation of Societies of Biological Psychiatry guidelines on the assessment and pharmacological treatment of compulsive sexual behaviour disorder > Co-occurring conditions > Co-occurring psychiatric disorders
What the sources say
- Not checked yetcites Gregorio Hertz, Turner, et al. 2022
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In a sample of 90 individuals diagnosed with high-functioning autism, 23.3% showed signs of CSB compared to 6% in the control group from the general population (Schöttle et al. 2017).”
§ The World Federation of Societies of Biological Psychiatry guidelines on the assessment and pharmacological treatment of compulsive sexual behaviour disorder > Co-occurring conditions > Co-occurring psychiatric disorders
What the sources say
- Not checked yetcites Schöttle et al. 2017
plainstates an associationn = 90- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In a study from Brazil including 458 people with gambling disorder, 6.4% reported CSB that fulfilled criteria to be considered as a psychiatric disorder (Tang et al. 2020).”
§ The World Federation of Societies of Biological Psychiatry guidelines on the assessment and pharmacological treatment of compulsive sexual behaviour disorder > Co-occurring conditions > Co-occurring psychiatric disorders
What the sources say
- Not checked yetcites Tang et al. 2020
plainn = 458- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At the time of the writing of these guidelines, two studies evaluated the efficacy of psychoeducational interventions for CSB.”
§ The World Federation of Societies of Biological Psychiatry guidelines on the assessment and pharmacological treatment of compulsive sexual behaviour disorder > Treatment of CSBD > Psychological treatment of CSB
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
196 more claims
Create a free account to see all 379 claims and to verify the 354 references still open.
- It may state two separate claims as one. 127
- Probably not a substantial claim. 66
- The quote only partly states this claim. 3
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It deeply affects sexual well-being and the ability to form and maintain satisfactory emotional and sexual relationships; therefore, it should be treated with a transtheoretical and multimodal approach to provide more holistic and individualized therapeutic care.15,102,147,148-150”
From Assessment and treatment of compulsive sexual behavior disorder: a sexual medicine perspective (2024) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At level 2, either selective serotonin reuptake inhibitors (eg, escitalopram) or the opioid receptor antagonist naltrexone is considered.”
From Assessment and treatment of compulsive sexual behavior disorder: a sexual medicine perspective (2024) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Again, to varying degrees, they recognize the influence of the dual control73,145 and tipping point models74,146 but incorporate other theories (eg, family systems and social learning, cognitive and behavioral, attachment and interpersonal15,102) and address the importance of sociocultural influences (eg, moral incongruence,14,59,60 erotic conflicts, and minority stress143).”
From Assessment and treatment of compulsive sexual behavior disorder: a sexual medicine perspective (2024) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These treatment choices depend on the following15: - Motivation and compliance - Severity of CSBD symptoms with a special focus on failure to control sexual impulses and urges - Type of CSBD (autoerotic or partnered) and relationship status”
From Assessment and treatment of compulsive sexual behavior disorder: a sexual medicine perspective (2024) · cites this paper as [15]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There can be an increased risk of sexually transmitted infections or other health problems.15,16”
From Assessment and treatment of compulsive sexual behavior disorder: a sexual medicine perspective (2024) · cites this paper as [15]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The World Federation of Societies of Biological Psychiatry guidelines on the assessment and pharmacological treatment of compulsive sexual behaviour disorder > Pharmacological treatment > Selective serotonin reuptake inhibitors (two case reports, four open studies and two RCTs)
“Sertraline mean dose 99.0 mg, SD = 62.8 mg/day”
§ The World Federation of Societies of Biological Psychiatry guidelines on the assessment and pharmacological treatment of compulsive sexual behaviour disorder > Pharmacological treatment > Selective serotonin reuptake inhibitors (two case reports, four open studies and two RCTs)
“The mean sertraline dose was 99.0 mg/day (SD = 61.8 mg/day).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“N = 127 men convicted for sexual offences currently imprisoned with hyper-arousal, intrusive sexual fantasies or urges, or dangerous paraphilias | 83% in sex offender treatment program | Cyproterone acetate (CPA) at 50–100 mg/d (16 patients) Fluoxetine or paroxetine 20–60 mg/day (75 patients) SSRI + CPA (7 patients) GnRH-agonists (two patients) No medication (20 patients)”
§ The World Federation of Societies of Biological Psychiatry guidelines on the assessment and pharmacological treatment of compulsive sexual behaviour disorder > Pharmacological treatment > Cyproterone acetate (CPA) (one case report, one open study in patients with CSB and comorbid paraphilic disorders)
Reported 127 · recomputed 120
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The World Federation of Societies of Biological Psychiatry guidelines on the assessment and pharmacological treatment of compulsive sexual behaviour disorder > Pharmacological treatment > Selective serotonin reuptake inhibitors (two case reports, four open studies and two RCTs)
“Paroxetine 20 mg/day Treatment duration between 14.5 and 20.5 weeks”
§ The World Federation of Societies of Biological Psychiatry guidelines on the assessment and pharmacological treatment of compulsive sexual behaviour disorder > Pharmacological treatment > Selective serotonin reuptake inhibitors (two case reports, four open studies and two RCTs)
“these adverse effects diminished within the 10-week study period.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The World Federation of Societies of Biological Psychiatry guidelines on the assessment and pharmacological treatment of compulsive sexual behaviour disorder > Pharmacological treatment > Selective serotonin reuptake inhibitors (two case reports, four open studies and two RCTs)
“1 patient imipramine 225 mg/day, 1 patient lithium 1500 mg/day, 1 patient imipramine 125 mg/day + lithium 600 mg/day”
§ The World Federation of Societies of Biological Psychiatry guidelines on the assessment and pharmacological treatment of compulsive sexual behaviour disorder > Pharmacological treatment > Selective serotonin reuptake inhibitors (two case reports, four open studies and two RCTs)
“one was treated with imipramine (125 mg/day), one with impramine (225 mg/day) and lithium (600 mg/day)”
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
&NA; (1988) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198802020-00022 · Cited by 12,526
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Encyclopedia of the Neurological Sciences · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,117
Acceptance and commitment therapy: model, processes and outcomes
Hayes, S. C., Luoma, J. B., Bond, F. W., Masuda, A., & Lillis, J. (2006) · Behaviour Research and Therapy · doi:10.1016/j.brat.2005.06.006 · Cited by 6,587
Sexual Behavior in the Human Male
(1948) · Physical Therapy · doi:10.1093/ptj/28.2.93 · Cited by 5,134
Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors
Washton, A. M. (1986) · Journal of Studies on Alcohol · doi:10.15288/jsa.1986.47.260 · Cited by 2,527
McCormack, S., Dunn, D. T., Desai, M., Dolling, D. I., Gafos, M., Gilson, R., Sullivan, A. K., Clarke, A., Reeves, I., Schembri, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00056-2 · Cited by 1,878
Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS)
Lefaucheur, J.-P., Antal, A., Ayache, S. S., Benninger, D. H., Brunelin, J., Cogiamanian, F., Cotelli, M., De Ridder, D., Ferrucci, R., Langguth, B., et al. (2017) · Clinical Neurophysiology · doi:10.1016/j.clinph.2016.10.087 · Cited by 1,826
Impulse Control Disorders in Parkinson Disease: A Cross-Sectional Study of 3090 Patients
Weintraub, D., Koester, J., Potenza, M. N., Siderowf, A. D., Stacy, M., Voon, V., Whetteckey, J., Wunderlich, G. R., & Lang, A. E. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.65 · Cited by 1,487
Self-citationHypersexual disorder: A proposed diagnosis for DSM-V
Kafka, M. P. (2010) · Archives of Sexual Behavior · doi:10.1007/s10508-009-9574-7 · Cited by 1,095
Research works printed but not linked: 9
- Briken P, Turner D. 2021. Pharmacotherapy for patients with CSBD. In: Compulsive sexual behavior disorder. Washington (DC): American Psychiatric Association Publishing; p. 95–108.
- Carnes P. 1989. Contrary to love: Helping the sexual addict. Minneapolis, MN: CompCare.
- 10.1080/10720162.2013.772873 · doi:10.1080/10720162.2013.772873
- Ciocca G, Nimbi FM, Limoncin E, Mollaioli D, Marchetti D, Verrocchio MC, Simonelli C, Jannini EA, Fontanesi L. 2020. Italian validation of the Hypersexual Behavior Inventory (HBI): psychometric characteristics of a self-report tool evaluating a psychopathological facet of sexual behavior. J Psychopathol. 26:169–175.
- Hayden D. 2013. Total sex addiction recovery: a guide to therapy. Bloomington (IN): Xlibris US.
- Hergüner S, Hergüner A, Cicek E. 2012. Combination of risperidone and paroxetine for inappropriate sexual behaviors in an adolescent with autism and mental retardation. Arch Neuropsychiatry. 49:311–313.
- Rösler M, Retz W, Turner D. 2020. Pharmacotherapy of ADHD in adults. In: Riederer P, Laux G, Nagatsu T, Le W, Riederer C, editors. NeuroPsychopharmacotherapy. Cham: Springer International Publishing; p. 1–18.
- Savard J. 2021. Compulsive sexual behavior disorder: clinical characteristics and treatment with Naltrexone [dissertation]. Umeå: Umeå University.
- Stekel W. 2013. Onanie und Homosexualität: Die homosexuelle Neurose [Onanism and homosexuality. The homosexual neurosis]. Bremen: Bremen University Press
Cited by
Current Advances in Behavioral Addictions: From Fundamental Research to Clinical Practice
Brand, M., Antons, S., Bőthe, B., Demetrovics, Z., Fineberg, N. A., Jiménez‐Múrcia, S., King, D. L., Mestre‐Bach, G., Moretta, T., Müller, A., et al. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240092 · Cited by 173
“Other well-validated scales for CSexBD and PPU only partly assess ICD-11 criteria (46).”
Self-citationAssessment and treatment of compulsive sexual behavior disorder: a sexual medicine perspective
Briken, P., Bőthe, B., Carvalho, J., Coleman, E., Giraldi, A., Kraus, S. W., Lew-Starowicz, M., & Pfaus, J. G. (2024) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qeae014 · Cited by 55
“While these algorithms exist, more evidence is needed on pharmacologic interventions in CSBD.”
BackgroundInfluentialSelf-citationBőthe, B., Vaillancourt‐Morel, M., Bergeron, S., Hermann, Z., Ivaskevics, K., Kraus, S. W., & Grubbs, J. B. (2024) · Journal of Psychopathology and Clinical Science · doi:10.1037/abn0000913 · Cited by 57
Self-citationHoward, L. M., Wilson, C. A., Reilly, T. J., Moss, K. M., Mishra, G. D., Coupland‐Smith, E., Riecher‐Rössler, A., Seedat, S., Smith, S. M., Steinberg, J. R., et al. (2025) · World Psychiatry · doi:10.1002/wps.21305 · Cited by 62
“Indeed, use of dopamine agonists is associated with compulsive sexual behavior 144 .”
Koós, M., Nagy, L., Kraus, S. W., Demetrovics, Z., Potenza, M. N., Gaudet, É., Ballester‐Arnal, R., Batthyány, D., Bergeron, S., Billieux, J., et al. (2024) · The Journal of Sex Research · doi:10.1080/00224499.2024.2359641 · Cited by 34
“…PU could be a fruitful direction for future studies aiming to identify at-risk populations for prevention or intervention programs (Bőthe, Baumgartner, et al., 2021), or evaluating novel treatments for help seeking populations (Antons et al., 2022; Markert et al., 2023; Turner et al., 2022).”
Self-citation
Metadata
- Authors
- Turner, D., Briken, P., Grubbs, J., Malandain, L., Mestre-Bach, G., Potenza, M. N., & Thibaut, F.
- Affiliations
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Bowling Green State University (US)
- Department of Psychiatry and Addictive Disorders, University Hospital Cochin (site Tarnier) AP-HP, Paris, France
- Facultad de Ciencias de la Salud, Universidad Internacional de La Rioja, La Rioja, Spain
- Yale University (US)
- Inserm (FR)
- Corresponding author
- Turner, Daniel
- Thibaut, Florence
- ORCID
- Venue
- Dialogues in Clinical Neuroscience
- Publisher
- Informa UK Limited
- Published
- 2022-11-17
- Volume
- 24
- Issue
- 1
- Pages
- 10-69
- ISSN
- 1294-8322 (ISSN-L)
- 1958-5969
- PMC
- PMC10408697
- OpenAlex
- W4309426955
- Cited by
- 86
- References
- 411
- Citations by year
- 2026: 28 · 2025: 25 · 2024: 16 · 2023: 14 · 2022: 2
- FWCI
- 13.00
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Dialogues in Clinical Neuroscience (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- Re-Unir (International University of La Rioja) (submittedVersion, other-oa)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Sexuality, Behavior, and Technology
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Social Sciences › Psychology › Clinical Psychology › Gambling Behavior and Treatments
- Keywords
- pharmacotherapy, selective serotonin reuptake inhibitors, naltrexone, paraphilic disorders, chemsex, hormone therapy, psychoeducation, psychotherapy, treatment algorithm, psychiatric comorbidity
- MeSH terms
- Adult, Biological Psychiatry, Compulsive Behavior, Humans, Paraphilic Disorders, Sexual Behavior, Sexual Dysfunctions, Psychological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The World Federation of Societies of Biological Psychiatry guidelines on the assessment and pharmacological treatment of compulsive sexual behaviour disorder. https://app.cochat.ai/papers/10.1080/19585969.2022.2134739
- The paper
- Turner, D., Briken, P., Grubbs, J., Malandain, L., Mestre-Bach, G., Potenza, M. N., & Thibaut, F. (2022). The World Federation of Societies of Biological Psychiatry guidelines on the assessment and pharmacological treatment of compulsive sexual behaviour disorder. Dialogues in Clinical Neuroscience. https://doi.org/10.1080/19585969.2022.2134739
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.